Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways

European Journal of Pharmacology

Volumn 735, Issue 1, 2014, Pages 184-192

  Park, Sumin ^a   Regmi, Sushil Chandra ^a   Park, Su Young ^a   Lee, Eun Kyoung ^a   Chang, Jae Hoon ^a   Ku, Sae Kwang ^b   Kim, Dong Hee ^c   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

^b Daegu Hany University   (South Korea)

^c Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

7 O succinyl macrolactin A; Colitis; mTOR; NF B; Rapamycin

Indexed keywords

7 O SUCCINYLMACROLACTIN A; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MESALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISOLONE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 7-O-SUCCINYL MACROLACTIN A; CYTOKINE; MACROLIDE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL INFILTRATION; COLITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; EDEMA; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SCORING SYSTEM; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; WEIGHT REDUCTION; ANIMAL; CELL SURVIVAL; CHEMICALLY INDUCED; COLON; DRUG EFFECTS; GENETICS; HT 29 CELL LINE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; U937 CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CELL SURVIVAL; COLITIS; COLON; CYTOKINES; FEMALE; HT29 CELLS; HUMANS; MACROLIDES; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; TOR SERINE-THREONINE KINASES; TRINITROBENZENESULFONIC ACID; U937 CELLS;

EID: 84899774975     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.04.024     Document Type: Article

References (49)

1. A.S. Baldwin Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights Annu. Rev. Immunol. 14 1996 649 683 (Pubitemid 26130197)
2. R.E. Banks, A.J. Gearing, I.K. Hemingway, D.R. Norfolk, T.J. Perren, and P.J. Selby Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies Br. J. Cancer 68 1993 122 124 (Pubitemid 23178563)
3. P.J. Barnes, and M. Karin Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N. Engl. J. Med. 336 1997 1066 1071 (Pubitemid 27163860)
4. M.R. Bhonde, R.D. Gupte, S.D. Dadarkar, M.G. Jadhav, A.A. Tannu, P. Bhatt, D.R. Bhatia, N.K. Desai, V. Deore, and N. Yewalkar A novel mTOR inhibitor is efficacious in a murine model of colitis Am. J. Physiol. Gastrointest. Liver Physiol. 295 2008 G1237 G1245
5. C.C. Chen, and A.M. Manning Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-kappa B Agents Actions Suppl. 47 1995 135 141
6. G. DHaens, L. Lemmens, K. Geboes, L. Vandeputte, F. Van Acker, L. Mortelmans, M. Peeters, S. Vermeire, F. Penninckx, F. Nevens, M. Hiele, and P. Rutgeerts Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 2001 1323 1329 (Pubitemid 32322305)
7. H.C. Dan, M.J. Cooper, P.C. Cogswell, J.A. Duncan, J.P. Ting, and A.S. Baldwin Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK Genes Dev. 22 2008 1490 1500 (Pubitemid 351793083)
8. W. Dippold, B. Wittig, W. Schwaeble, W. Mayet, and K.H. Meyer zum Buschenfelde Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells Gut 34 1993 1593 1597 (Pubitemid 23341854)
9. R. Duchmann, I. Kaiser, E. Hermann, W. Mayet, K. Ewe, and K.H. Büschenfelde Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin. Exp. Immunol. 102 1995 448 455 (Pubitemid 26013210)
10. L.J. Egan, D.C. Mays, C.J. Huntoon, M.P. Bell, M.G. Pike, W.J. Sandborn, J.J. Lipsky, and D.J. McKean Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity J. Biol. Chem. 274 1999 26448 26453
11. R.D. Ellis, J.R. Goodlad, G.A. Limb, J.J. Powell, R.P. Thompson, and N.A. Punchard Activation of nuclear factor kappa B in Crohns disease Inflamm. Res. 47 1998 440 445 (Pubitemid 28532654)
12. C.O. Elson, and C.T. Weaver Experimental mouse models of inflammatory bowel disease: new insights into pathogenic mechanisms Inflammatory Bowel Disease: From Bench to Bedside 2005 Springer 67 99
13. S. Farkas, M. Hornung, C. Sattler, M. Guba, M. Steinbauer, M. Anthuber, H. Herfarth, H.J. Schlitt, and E.K. Geissler Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis Int. J. Colorectal Dis. 21 2006 747 753 (Pubitemid 44524028)
14. S. Ghosh, and M. Karin Missing pieces in the NF-kappaB puzzle Cell 109 Suppl. 2002 S81 S96
15. H. Glantschnig, J. Fisher, G. Wesolowski, G. Rodan, and A. Reszka M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase Cell Death Differ. 10 2003 1165 1177 (Pubitemid 37258582)
16. K. Gustafson, M. Roman, and W. Fenical The macrolactins, a novel class of antiviral and cytotoxic macrolides from a deep-sea marine bacterium J. Am. Chem. Soc. 111 1989 7519 7524 (Pubitemid 19232716)
17. E. Hatano, and D.A. Brenner Akt protects mouse hepatocytes from TNF-α-and Fas-mediated apoptosis through NK-κB activation Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G1357 G1368
18. A.R. Jurjus, N.N. Khoury, and J.M. Reimund Animal models of inflammatory bowel disease J. Pharmacol. Toxicol. Methods 50 2004 81 92 (Pubitemid 39286320)
19. G.C. Kaiser, F. Yan, and D.B. Polk Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes Gastroenterology 116 1999 602 609 (Pubitemid 29106768)
20. C.T. Keith, and S.L. Schreiber PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints Science-New York then Washington 1995 (50-50)
21. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317
22. D.H. Kim, H.K. Kim, K.M. Kim, C.K. Kim, M.H. Jeong, C.Y. Ko, K.H. Moon, and J.S. Kang Antibacterial activities of macrolactin a and 7-O-succinyl macrolactin a from Bacillus polyfermenticus KJS-2 against vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus Arch. Pharmacal Res. 34 2011 147 152
23. H. Kim, S. Hwang, W. Kim, I. Ryoo, C. Kim, J. Suk, K. Han, and I. Yoo Neuronal cell protection activity of macrolactin A produced by Actinomadura sp J. Microbiol. Biotechnol 1997 7
24. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models Gastroenterology 87 1984 1344 1350 (Pubitemid 15201434)
25. B. Li, P.Y. Cheung, X. Wang, S.W. Tsao, M.T. Ling, Y.C. Wong, and A.L. Cheung Id-1 activation of PI3K/Akt/NFκB signaling pathway and its significance in promoting survival of esophageal cancer cells Carcinogenesis 28 2007 2313 2320 (Pubitemid 350111589)
26. S. Lichtiger, D.H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, F. Michelassi, and S. Hanauer Cyclosporine in severe ulcerative colitis refractory to steroid therapy N. Eng. J. Med. 330 1994 1841 1845 (Pubitemid 24188135)
27. C.G. Loftus, E.V. Loftus Jr., and W.J. Sandborn Cyclosporin for refractory ulcerative colitis Gut 52 2003 172 173 (Pubitemid 36115054)
28. D.C. Massey, F. Bredin, and M. Parkes Use of sirolimus (rapamycin) to treat refractory Crohns disease Gut 57 2008 1294 1296
29. S. Nikolaus, J. Bauditz, P. Gionchetti, C. Witt, H. Lochs, and S. Schreiber Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation Gut 42 1998 470 476 (Pubitemid 28186561)
30. H. Ogino, K. Nakamura, T. Iwasa, E. Ihara, H. Akiho, Y. Motomura, K. Akahoshi, H. Igarashi, M. Kato, K. Kotoh, T. Ito, and R. Takayanagi Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model J. Gastroenterol. 47 2012 366 376
31. O.N. Ozes, L.D. Mayo, J.A. Gustin, S.R. Pfeffer, L.M. Pfeffer, and D.B. Donner NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase Nature 401 1999 82 85
32. F. Pallone, and G. Monteleone Regulatory cytokines in inflammatory bowel disease Aliment. Pharmacol. Ther. 10 Suppl. 2 1996 75 79 (discussion 80) (Pubitemid 26341299)
33. J. Paul, A.K. Verma, and R. Verma Role of gut flora in inflammatory bowel disease-a state of art Communicating Current Research and Educational Topics and Trends in Applied Microbiology 2007 705 718
34. L. Peran, D. Camuesco, M. Comalada, A. Nieto, A. Concha, M.P. Diaz-Ropero, M. Olivares, J. Xaus, A. Zarzuelo, and J. Galvez Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis World J. Gastroenterol. 11 2005 5185 5192 (Pubitemid 41410337)
35. D.K. Podolsky The current future understanding of inflammatory bowel disease Best Pract. Res. Clin. Gastroenterol. 16 2002 933 943
36. J. Rivera-Nieves, G. Gorfu, and K Ley Leukocyte adhesion molecules in animal models of inflammatory bowel disease Inflamm. Bowel Dis. 14 2008 1715 1735
37. M. Romero-Tabarez, R. Jansen, M. Sylla, H. Lunsdorf, S. Haussler, D.A. Santosa, K.N. Timmis, and G. Molinari 7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia Antimicrob. Agents Chemother. 50 2006 1701 1709
38. R. Rothlein, M. Czajkowski, M.M. ONeill, S.D. Marlin, E. Mainolfi, and V.J. Merluzzi Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies J. Immunol. 141 1988 1665 1669
39. S. Schreiber Immunopathophysiology of Inflammatory Bowel Disease, Immunological Aspects of Gastroenterology 2001 Springer 217 239
40. A.K. Spiik, A. Ridderstad, L.G. Axelsson, T. Midtvedt, L. Bjork, and S. Pettersson Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides Int. J. Colorectal Dis. 17 2002 223 232 (Pubitemid 36075776)
41. A.F. Stucchi, S. Shofer, S. Leeman, O. Materne, E. Beer, J. McClung, K. Shebani, F. Moore, M. OBrien, and J.M. Becker NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats Am. J. Physiol. Gastrointest. Liver Physiol. 279 2000 G1298 G1306
42. D. Thapa, J.S. Lee, S.Y. Park, Y.H. Bae, S.K. Bae, J.B. Kwon, K.J. Kim, M.K. Kwak, Y.J. Park, H.G. Choi, and J.A. Kim Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner J. Pharmacol. Exp. Ther 327 2008 353 364
43. D. Thapa, J.S. Lee, M.A. Park, M.Y. Cho, Y.J. Park, H.G. Choi, T.C. Jeong, and J.A. Kim Inhibitory effects of clotrimazole on TNF-alpha-induced adhesion molecule expression and angiogenesis Arch. Pharmacal Res. 32 2009 593 603
44. M.H. Thornhill, S.M. Wellicome, D.L. Mahiouz, J.S. Lanchbury, U. Kyan-Aung, and D.O. Haskard Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms J. Immunol. 146 1991 592 598
45. C. Tokunaga, K. Yoshino, and K. Yonezawa mTOR integrates amino acid- and energy-sensing pathways Biochem. Biophys. Res. Commun. 313 2004 443 446 (Pubitemid 37543606)
46. G. van Assche, and P. Rutgeerts Antiadhesion molecule therapy in inflammatory bowel disease Inflamm. Bowel Dis. 8 2002 291 300 (Pubitemid 34784983)
47. S.J. Van Deventer Tumour necrosis factor and Crohns disease Gut 40 1997 443 448 (Pubitemid 27204920)
48. R.J. Xavier, and D.K. Podolsky Unravelling the pathogenesis of inflammatory bowel disease Nature 448 2007 427 434 (Pubitemid 47123518)
49. M. Zareie, P.K. Singh, E.J. Irvine, P.M. Sherman, D.M. McKay, and M.H. Perdue Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohns disease Am. J. Pathol. 158 2001 1101 1109 (Pubitemid 32221802)